{"nctId":"NCT01259128","briefTitle":"Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia","startDateStruct":{"date":"2010-04"},"conditions":["Nocturia"],"count":32,"armGroups":[{"label":"SER120 500 ng/day","type":"EXPERIMENTAL","interventionNames":["Drug: SER120 Nasal Spray 500 ng/day"]},{"label":"SER120 750 ng/day","type":"EXPERIMENTAL","interventionNames":["Drug: SER120 nasal spray 750 ng/day"]}],"interventions":[{"name":"SER120 Nasal Spray 500 ng/day","otherNames":[]},{"name":"SER120 nasal spray 750 ng/day","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male \\& female greater or equal to 75 years of age, history of nocturia\n\nExclusion Criteria:\n\n* CHF, Diabetes, Diabetes Insipidus, Renal Insufficiency, Heptatic Insufficiency, Incontinence, Illness requiring steroid, current or past urologic maliganancy, nephrotic syndrome\n* Unexplained pelvic masses\n* Urinary bladder surgery or radiotherapy\n* Sleep apnea","healthyVolunteers":false,"sex":"ALL","minimumAge":"75 Years","maximumAge":"95 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Serum Sodium Levels at Baseline and During Treatment","description":"Mean serum sodium reported at baseline, Day 4, Day 8, Day 15, Day 22, Day 29, Day 43 and Day 57.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"141.0","spread":"2.4"},{"groupId":"OG001","value":"140.0","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139.2","spread":"3.0"},{"groupId":"OG001","value":"140.3","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139.1","spread":"3.2"},{"groupId":"OG001","value":"140.4","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140.4","spread":"2.1"},{"groupId":"OG001","value":"140.2","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139.5","spread":"3.2"},{"groupId":"OG001","value":"140.0","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139.7","spread":"2.7"},{"groupId":"OG001","value":"139.7","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139.9","spread":"2.7"},{"groupId":"OG001","value":"139.6","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140.9","spread":"2.6"},{"groupId":"OG001","value":"141.1","spread":"1.7"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Nocturic Episodes Per Night","description":"Change in mean nocturic episodes per night between baseline and Week 8","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"0.8"},{"groupId":"OG001","value":"-1.4","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Percent of Participants With Greater or Equal to 50% Reduction in the Number of Nocturic Episodes","description":"Percent of participants with greater or equal to 50% reduction in number of nocturic episodes at Week 8 compared to Baseline","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":["nasal discomfort","sneezing","lacrimation increased","rhinorrhea","diarrhea"]}}}